Cybin Inc. CYBN
We take great care to ensure that the data presented and summarized in this overview for CYBIN INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYBN
View all-
Virtu Financial LLC New York, NY118KShares$1.47 Million0.0% of portfolio
-
Emfo, LLC24.5KShares$305,4480.01% of portfolio
-
Unique Wealth Strategies, LLC Burr Ridge, IL12.7KShares$158,3710.0% of portfolio
-
Victory Financial Group, LLC Austin, TX11.7KShares$146,1530.0% of portfolio
-
Covington Capital Management10KShares$124,8000.0% of portfolio
-
Kistler Tiffany Companies, LLC Berwyn, PA3.6KShares$44,9280.0% of portfolio
-
American Portfolios Advisors Holbrook, NY2.5KShares$31,2000.0% of portfolio
-
Westside Investment Management, Inc.1KShares$12,4800.0% of portfolio
-
Column Capital Advisors, LLC900Shares$11,2320.0% of portfolio
-
Mc Ilrath & Eck, LLC400Shares$4,9920.0% of portfolio
Latest Institutional Activity in CYBN
Top Purchases
Top Sells
About CYBN
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Insider Transactions at CYBN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|